metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
mEC - (neo)adjuvant (NA) metastatic/advanced - esophageal cancer (mEC) mEC - (neo)adjuvant (NA)
versus placebo
	nivolumab alone
	CheckMate 577, 2021 N Engl J Med 2021 Apr 1;384(13):1191-1203. NCT02743494	RCT	mEC - (neo)adjuvant (NA)	nivolumab	placebo	as adjuvant therapy in patientswith locally advanced (Adults with resected (R0)stage II or III) esophageal or gastroesophageal junction cancer with predominant adenocarcinomaor squamous-cell carcinoma.	532 / 262	some concern	conclusif	demonstrated 37 % decrease in events or deaths (EFS) (PE)
mEC - 1st line (L1) metastatic/advanced - esophageal cancer (mEC) mEC - 1st line (L1)
versus placebo plus SoC
	pembrolizumab plus SoC
	KEYNOTE-590 unpublished Future Oncol 2019 Apr;15(10):1057-1066. Lancet. 2021 Aug 28;398(10302):759-771 NCT03189719	RCT	mEC - 1st line (L1)	Pembrolizumab with cisplatin and 5 FU :	placebo with cisplatin and 5 FU :	as first-line treatment in Subjects With Advanced/Metastatic Esophageal squamous Carcinoma or EGJ	373 / 376	NA	conclusif	demonstrated 27 % decrease in deaths (OS) (PE) demonstrated 35 % decrease in progression or deaths (PFS) (PE) demonstrated 98 % increase in objective responses (ORR) (PE) Pembrolizumab (Keytruda) in combination with chemotherapy significantly improved overallsurvival (OS) and progressionfree survival (PFS) in the frontline treatment of patients with locally advanced or metastatic esophageal cancer, meeting the primary end points of the phase 3 KEYNOTE-590 trial
mEC - 2nd line (L2) metastatic/advanced - esophageal cancer (mEC) mEC - 2nd line (L2)
versus Standard of Care (SoC)
	camrelizumab alone
	ESCORT, 2020 Lancet Oncol. 2020; : NCT03099382	RCT	mEC - 2nd line (L2)	camrelizumab	docetaxel or irinotecan	patients aged 18 to 75 years with a histological or cytological diagnosis of advanced or metastatic oesophageal squamous cell carcinoma, had progressed on, or were intolerant to, first-line standard therapy.	228 / 220	high	conclusif	demonstrated 29 % decrease in deaths (OS),deaths (OS) (PE) suggested 31 % decrease in progression or deaths (PFS),progression or deaths (PFS)
	nivolumab alone
	ATTRACTION-3, 2019 Lancet Oncol 2019 Nov;20(11):1506-1517. NCT02569242	RCT	mEC - 2nd line (L2)	Nivolumab	ICC Docetaxel/Paclitaxel	Patients With Unresectable Advanced or Recurrent (squamous or adenosquamous) Esophageal (including the oesophagogastric junction) Cancer who have failed in standard chemotherapies.	210 / 209	high	conclusif	demonstrated 23 % decrease in deaths (OS) (PE) statistically significant 64 % decrease in DCR
	pembrolizumab alone
	KEYNOTE-181, 2020 Journal of Clinical Oncology Journal of Clinical Oncology J Clin Oncol 2020 Dec 10;38(35):4138-4148. Pubmed J Clin Oncol 2021 Nov 3;JCO2100601. ESMO Open. 2022 Feb;7(1):100341. NCT02564263	RCT	mEC - 2nd line (L2)	Pembrolizumab	chemotherapy ICC (paclitaxel, docetaxel, or irinotecan)	Subjects With Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus/ or Siewert type I adenocarcinoma of the esophagogastric junction (EGJ) That Have Progressed After First-Line Standard Therapy	314 / 314	NA	inconclusive	inconclusive 11 % decrease in deaths (OS) (PE) (Pembrolizumab significantly improved OS compared with chemo as second-line therapy for advanced esophageal cancer with PD-L1 CPS ≥10) => no stat plan

mEC - (neo)adjuvant (NA) metastatic/advanced - esophageal cancer (mEC) mEC - (neo)adjuvant (NA)

mEC - 1st line (L1) metastatic/advanced - esophageal cancer (mEC) mEC - 1st line (L1)

mEC - 2nd line (L2) metastatic/advanced - esophageal cancer (mEC) mEC - 2nd line (L2)